Please Wait
Applying Filters...
menu
    • menu
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Lorlatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer's Lorbrena Sets Longest PFS Record in Advanced NSCLC
    Pfizer's Lorbrena Sets Longest PFS Record in Advanced NSCLC

    29 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260526978972/en/Seven-Year-Analysis-from-Pfizers-LORBRENA-CROWN-Trial-Shows-Longest-Progression-Free-Survival-Reported-to-Date-in-Advanced-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    29 May 2026
    Share Share
    Pfizer and Strata expand clinical partnership for cancer trial
    Pfizer and Strata expand clinical partnership for cancer trial

    14 Sep 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/pfizer-strata-partnership-cancer-trial/

    CLINICALTRIALSARENA
    14 Sep 2022
    Share Share
    Amber Specialty Added to Pfizer’s Limited Distribution Network
    Amber Specialty Added to Pfizer’s Limited Distribution Network

    03 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220803005649/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share
    Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC
    Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC

    19 May 2022

    // Kim Yun-mi KOREABIOMED

    http://www.koreabiomed.com/news/articleView.html?idxno=13724

    Kim Yun-mi KOREABIOMED
    19 May 2022
    Share Share
    EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC
    EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC

    28 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220128005304/en

    BUSINESSWIRE
    28 Jan 2022
    Share Share
    Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc
    Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc

    04 Mar 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=135923&sid=2

    PHARMABIZ
    04 Mar 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.